Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.
about
Drug-induced diabetes mellitusThe 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of riskThe 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of riskThe "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst.Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT?Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndromeReview article: pancreatic renin-angiotensin systems in health and diseaseDiagnosis and management of the metabolic syndrome in obesityStroke prevention in diabetes and obesityCardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysisBlood pressure and the risk of developing diabetes in african americans and whites: ARIC, CARDIA, and the framingham heart studyLife-course socioeconomic position and incidence of diabetes mellitus among blacks and whites: the Alameda County Study, 1965-1999Diabetic nephropathy - Epidemiology in Asia and the current state of treatmentHigh body mass index is an important risk factor for the development of type 2 diabetes.Treatment of hypertension in obese patients.The diabetes-obesity-hypertension nexus in Qatar: evidence from the World Health Survey.Pharmacologic Update - Beta Blockers in Treatment of Heart Failure and Hypertension in Diabetes: Ugly Misconceptions Slain by Beautiful Clinical Data.Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR studyDiabetes and urbanization in the Omani population: an analysis of national survey dataSleep-disordered breathing and glucose metabolism in hypertensive men: a population-based study.Antihypertensive drug class and impaired fasting glucose: a risk association study among Chinese patients with uncomplicated hypertension.Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.Medication use following bariatric surgery: factors associated with early discontinuation.Association of NOS3 Glu298Asp SNP with hypertension and possible effect modification of dietary fat intake in the ARIC study.Additive effects of cilnidipine, an L-/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus.Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndromeDynamics of insulin action in hypertension: assessment from minimal model interpretation of intravenous glucose tolerance test data.Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysisWalking and running produce similar reductions in cause-specific disease mortality in hypertensives.Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study.The renin angiotensin system and the metabolic syndromeCoincidence of diabetes mellitus and hypertension in a semi-urban Cameroonian population: a cross-sectional study.Antihypertensive drugs and glucose metabolismCo-occurrence of diabetes and hypertension: pattern and factors associated with order of diagnosis among nigerians.Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalinkContinuous renal replacement therapy may increase the risk of catheter infection.Epidemiological and clinical studies on insulin resistance and diabetes.Pathophysiologic therapeutic targets in hypertension: a cardiological point of view.Reduced total and cause-specific mortality from walking and running in diabetes.Renal protection in diabetes: lessons from ONTARGET.
P2860
Q22306015-8CCB8005-F39B-4043-9AB0-ACF1403D289FQ24651499-27217ED2-B2E4-4C1A-B466-FA47439AE71CQ24652860-55D559DC-5CDE-4CB5-BDA5-3CD2EC4C3516Q24796000-F6CF59B1-3A6D-4CEC-8CA9-A2D818EE4CF7Q24799267-C310C112-4E84-4A70-A78E-CBC767A0543AQ24816197-D5A01411-18B3-4FD9-B5DD-9997727484D0Q26821967-E95D9030-48EC-4F00-BBA2-FABAA22805E7Q28192856-2C012512-B08A-41A5-8862-A8EEA8481283Q28200179-81496F2C-CC2C-4B52-BDD5-296DCF15E1C5Q28200196-0B49A770-04B3-4DA5-8AB0-F29EA8C9D842Q28387157-8A448D00-EDC3-4EEB-8D01-F959D24C8133Q28392547-E6375EC9-73AE-444F-827A-E75A6EA559CBQ28742785-EF446EAE-43FD-416B-B8C2-9D1D239A442EQ30422924-75396F93-E751-4E22-9238-8AF5ACD1E07EQ30429298-99A16331-3585-4326-AB97-959B17C8AD02Q30586511-F6A9F20A-6A17-4C1B-8E34-6144E1777000Q30654695-44DEF335-C58F-4423-942A-D8C67627185AQ30711948-6D010696-B62B-48F0-8095-D982B21926DEQ31037800-67F04F4C-E21C-4930-9DA0-F12176FCC877Q32155167-06AA4386-3BAD-45DF-BC4B-0822158D5F0DQ33368482-C6245CD1-EB6B-4AA9-A311-D7F6FDDA142EQ33561456-FBF0DD12-4D18-4D08-9B36-3C1C8ECDBDA0Q33591031-75611909-B633-4969-849B-EC43A595D9E8Q33685990-6848510F-AE84-4985-8D3F-4AEAC439A37FQ33800185-5B8E974F-894A-4CCA-ADEB-4BDAC56B721DQ33840829-419787B9-732F-4D33-BAD5-A9CC0E16DE52Q33857502-58BEA414-2AD1-4BEA-934D-56CB86512BBAQ33859058-516CE426-48DA-468A-B3BA-63C25AFD2397Q33875933-9017EC7A-DAB9-4065-BF21-93E18D807A69Q33898530-73F46227-D38E-4383-8B9D-9917C7EB7974Q33915412-63C0CFBE-7719-4A1C-8318-6C6097C9E4CCQ33938522-9F8877A0-F17A-482E-90F5-5B2C1793CAA9Q33948469-72264667-A27F-4D11-88F2-10B5B2F8FD44Q33950267-FED731EB-3DDA-4B6A-BB14-CA36CA0CDD35Q33986300-D0EBC27E-F463-4C7A-9880-B1EE69750962Q34075448-F70B434D-26DD-4DE0-8871-75CE6F8A6AD2Q34091890-690D2E9E-381A-445F-A6B8-D5FA280A2DA6Q34142036-C5C9CF39-FB04-4A1E-880A-CFDFB7728C02Q34150250-F19FD9AD-9F44-4201-A3D1-E147D08198E3Q34221460-D0646AFB-9B7A-4747-9C2C-AB283961D983
P2860
Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Hypertension and antihypertens ...... sis Risk in Communities Study.
@en
Hypertension and antihypertens ...... sis Risk in Communities Study.
@nl
type
label
Hypertension and antihypertens ...... sis Risk in Communities Study.
@en
Hypertension and antihypertens ...... sis Risk in Communities Study.
@nl
prefLabel
Hypertension and antihypertens ...... sis Risk in Communities Study.
@en
Hypertension and antihypertens ...... sis Risk in Communities Study.
@nl
P2093
P1476
Hypertension and antihypertens ...... sis Risk in Communities Study.
@en
P2093
P304
P356
10.1056/NEJM200003303421301
P407
P577
2000-03-01T00:00:00Z